Table 2.
Primary results testing effects of the intervention on immediate post-program scores and on slopes of change over all three assessments. Results presented include the F score, the degrees of freedom (df), significance level of the analysis (P), measures of effect size (eta2 and Cohen's d), and observed power (1-β).
| Post-Program | Slopes | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F | df | P | Eta2* | d | 1-β | F | df | P | Eta2* | d | 1-β | |
| Symptom Variables | ||||||||||||
| PSS | 14.58 | 88 | .000 | .14 | .48 | .97 | 6.29 | 88 | .014 | .07 | .54 | .70 |
| VAS | 3.41 | 87 | .068 | .04 | .32 | .45 | .82 | 87 | .368 | .01 | .12 | .15 |
| SSQ | 4.46 | 88 | .038 | .05 | .25 | .55 | 4.06 | 88 | .047 | .04 | .42 | .51 |
| FSI | 9.87 | 84 | .002 | .11 | .47 | .87 | 3.59 | 87 | .062 | .04 | .31 | .47 |
| FIQ Symptom Severity | 6.54 | 87 | .012 | .07 | .46 | .72 | 9.03 | 87 | .003 | .09 | .62 | .84 |
| FIQ Physical Functioning | 1.90 | 88 | .172 | .02 | .00 | .28 | 2.32 | 88 | .132 | .03 | .40 | .33 |
| Salivary Cortisol | ||||||||||||
| Diurnal Mean | .727 | 80 | .396 | .01 | .22 | .13 | .86 | 80 | .357 | .01 | .11 | .15 |
| Diurnal Slope | .000 | 80 | .988 | .00 | .36 | .05 | .26 | 80 | .610 | .00 | .00 | .08 |
| Mean Waking Value | .093 | 77 | .761 | .00 | .16 | .06 | .113 | 77 | .738 | .00 | .15 | .06 |
| CAR | 3.73 | 73 | .057 | .05 | .27 | .48 | .58 | 73 | .450 | .01 | .04 | .12 |
| CAR Slope | 2.96 | 74 | .090 | .04 | .41 | .40 | .583 | 74 | .448 | .01 | .02 | .12 |
Note.
Eta2 is the effect size indicating the proportion of the total variance attributed to the effect of treatment (calculated by dividing the sum-of-squares for an effect by the sum-of-squares total; small=.01, medium=.06, large=.14). PSS - Perceived Stress Scale, VAS - Visual Analog Scale, SSQ - Stanford Sleep Questionnaire, FSI - Fatigue Symptom Inventory, FIQ - Fibromyalgia Impact Questionnaire, CAR - cortisol awakening response